Diabetes drug raises bladder cancer risk

Data from a robust meta-analysis have reinforced concerns about the link between the Type 2 diabetes drug, pioglitazone, and bladder cancer.

The findings support guidance given last year to doctors by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency to regularly review patients' treatment with the drug and to avoid its use in those with a history of, or active, bladder cancer, or uninvestigated haematuria.

Based on three cohort studies involving more than 1.7 million patients, pioglitazone was associated with an estimated 22% increase in the risk of bladder cancer compared with those who had never taken the drug.

"This study quantifies the association between pioglitazone use and bladder cancer and may help inform decisions around safer use of pioglitazone in individuals with type 2 diabetes," say Jeffrey Johnson (University of Alberta, Edmonton, Canada) and colleagues.

The analysis, published in the Canadian Medical Association Journal, examined 10 studies of thiazolidinediones including 2,657,365 patients, with a bladder cancer incidence of 53.1 per 100,000 person-years. Of the five studies assessing pioglitazone exposure, each one reported an elevated or significantly increased risk of bladder cancer compared with patients who had never taken the drug.

However, last year - after assessing all available data at the time - the EMA concluded that the benefits of pioglitazone outweigh the risks for patients who respond well to treatment and have no alternative options.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Kirsty Oswald

Written by

Kirsty Oswald

Kirsty has a B.Sc. in Human Sciences from University College London. After several years working as medical copywriter, she became a medical journalist and is now freelance. Kirsty also works part-time as an editor for a London-based charity. She is particularly interested in the social and cultural aspects of science.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oswald, Kirsty. (2018, August 23). Diabetes drug raises bladder cancer risk. News-Medical. Retrieved on October 29, 2020 from https://www.news-medical.net/news/20120710/Diabetes-drug-raises-bladder-cancer-risk.aspx.

  • MLA

    Oswald, Kirsty. "Diabetes drug raises bladder cancer risk". News-Medical. 29 October 2020. <https://www.news-medical.net/news/20120710/Diabetes-drug-raises-bladder-cancer-risk.aspx>.

  • Chicago

    Oswald, Kirsty. "Diabetes drug raises bladder cancer risk". News-Medical. https://www.news-medical.net/news/20120710/Diabetes-drug-raises-bladder-cancer-risk.aspx. (accessed October 29, 2020).

  • Harvard

    Oswald, Kirsty. 2018. Diabetes drug raises bladder cancer risk. News-Medical, viewed 29 October 2020, https://www.news-medical.net/news/20120710/Diabetes-drug-raises-bladder-cancer-risk.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Inflammasome may play a key role in triggering immune response to cancer